What's new

Human medicines European public assessment report (EPAR): Litfulo, ritlecitinib, Date of authorisation: 15/09/2023, Revision: 4, Status: Authorised

Human medicines European public assessment report (EPAR): Litfulo, ritlecitinib, Date of authorisation: 15/09/2023, Revision: 4, Status: Authorised

Feb 27, 2025 - 13:57
 0
Human medicines European public assessment report (EPAR): Litfulo, ritlecitinib, Date of authorisation: 15/09/2023, Revision: 4, Status: Authorised
Human medicines European public assessment report (EPAR): Litfulo, ritlecitinib, Date of authorisation: 15/09/2023, Revision: 4, Status: Authorised
Read More

Tags:

Previous Article

Human medicines European public assessment report (EPAR): Remicade, infliximab, ...

Next Article

Human medicines European public assessment report (EPAR): Welireg, belzutifan, S...

Related Posts

Human medicines European public assessment report (EPAR): Nimenrix, meningococcal groups A, C, W-135 and Y conjugate vaccine, Date of authorisation: 20/04/2012, Revision: 41, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 13, 2025  0

Opinion/decision on a Paediatric investigation plan (PIP): Olumiant, Baricitinib, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Immune system disorders, PIP number: P/0520/2023

Opinion/decision on a Paediatric investigation plan (PI...

Feb 14, 2025  0

Orphan designation: Adeno-associated virus serotype 5 vector encoding C1-esterase inhibitor Treatment of hereditary angioedema, 10/11/2022 Withdrawn

Orphan designation: Adeno-associated virus serotype 5 v...

Feb 20, 2025  0